Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/12747
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRattanaumpawan P.
dc.contributor.authorUpapan P.
dc.contributor.authorThamlikitkul V.
dc.date.accessioned2021-04-05T03:05:31Z-
dc.date.available2021-04-05T03:05:31Z-
dc.date.issued2018
dc.identifier.issn0899823X
dc.identifier.other2-s2.0-85053002289
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/12747-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85053002289&doi=10.1017%2fice.2018.198&partnerID=40&md5=75e55793c32aed276d014061738c46e3
dc.description.abstractObjective We compared the effectiveness of antibiotic postprescription review and authorization (PPRA) determined by infectious disease (ID) clinical fellows with that of trained general pharmacists.Methods We conducted a noninferiority cluster-randomized controlled trial in 6 general medical wards at Siriraj Hospital in Bangkok, Thailand. Three wards were randomly assigned to the intervention (ie, the pharmacist PPRA group), and another 3 wards were assigned to the control (ie, the fellow PPRA group). We enrolled all patients in the study wards who received 1 or more doses of the targeted antibiotics: piperacillin/tazobactam, imipenem/cilastatin, and meropenem. The noninferiority margin was 10% for the favorable clinical response and 1.5 defined daily doses (DDDs) for the targeted antibiotics.Results We enrolled 303 patients in the pharmacist PPRA group and 307 patients in the ID fellow PPRA group. The baseline and clinical characteristics were similar in the 2 groups. The difference in the favorable response of patients who received the targeted antibiotics (ie, the pharmacist PPRA group minus the fellow PPRA group) was 5.15% (95% confidence interval [CI], -2.69% to 12.98%); the difference in the DDD of targeted antibiotic use (ie, the pharmacist PPRA group minus the fellow PPRA group) was 0.62 (95% CI, -1.57 to 2.82). We observed no significant difference in the DDD of overall antibiotics, 28-day mortality, 28-day ID-related mortality, favorable microbiological outcome, or antibiotic-associated complications.Conclusions We confirmed the noninferiority of pharmacist PPRA in terms of favorable clinical response; however, noninferiority in targeted antibiotic consumption could not be established. Therefore, using trained general pharmacists rather than ID clinical fellows could be an alternative in a resource-limited setting. Clinical trials registration: clinicaltrials.gov identifier: NCT 01797133 © 2018 by The Society for Healthcare Epidemiology of America. All rights reserved.
dc.subjectcilastatin plus imipenem
dc.subjectmeropenem
dc.subjectpiperacillin plus tazobactam
dc.subjectprescription drug
dc.subjectantiinfective agent
dc.subjectadult
dc.subjectantibiotic associated colitis
dc.subjectantibiotic postprescription review and authorization
dc.subjectantibiotic prophylaxis
dc.subjectantibiotic therapy
dc.subjectantimicrobial stewardship
dc.subjectbone infection
dc.subjectcardiovascular infection
dc.subjectcatheter infection
dc.subjectcentral nervous system infection
dc.subjectclinical outcome
dc.subjectcolitis
dc.subjectcommunity acquired infection
dc.subjectcomparative effectiveness
dc.subjectcontrolled study
dc.subjectdrug cost
dc.subjectdrug hypersensitivity
dc.subjectdrug induced disease
dc.subjectdrug response
dc.subjectdrug use
dc.subjectdrug utilization review
dc.subjectfemale
dc.subjectgastrointestinal infection
dc.subjectgenital tract infection
dc.subjecthead and neck infection
dc.subjecthospital infection
dc.subjecthospital mortality
dc.subjecthospital patient
dc.subjecthuman
dc.subjectinfectious arthritis
dc.subjectinfectious disease clinical fellow
dc.subjectintervention study
dc.subjectlength of stay
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical education
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectnose infection
dc.subjectpharmacist
dc.subjectpharyngitis
dc.subjectphysician
dc.subjectpneumonia
dc.subjectprescription
dc.subjectrandomized controlled trial
dc.subjectReview
dc.subjectskin infection
dc.subjectsoft tissue infection
dc.subjectsurgical infection
dc.subjectThailand
dc.subjecttreatment response
dc.subjecturinary tract infection
dc.subjectaged
dc.subjectcommunicable disease
dc.subjecthealth care facility
dc.subjecthealth care quality
dc.subjecthospital pharmacy
dc.subjectorganization and management
dc.subjectpharmacist
dc.subjectprocedures
dc.subjectstandards
dc.subjectvery elderly
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAnti-Bacterial Agents
dc.subjectAntimicrobial Stewardship
dc.subjectCommunicable Diseases
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPatients' Rooms
dc.subjectPharmacists
dc.subjectPharmacy Service, Hospital
dc.subjectStandard of Care
dc.subjectThailand
dc.titleA noninferiority cluster-randomized controlled trial on antibiotic postprescription review and authorization by trained general pharmacists and infectious disease clinical fellows
dc.typeReview
dc.rights.holderScopus
dc.identifier.bibliograpycitationInfection Control and Hospital Epidemiology. Vol 39, No.10 (2018), p.1154-1162
dc.identifier.doi10.1017/ice.2018.198
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.